Viatcheslav Rakov

2026

Achieving Minimal-to-No Pain in Women with Endometriosis Treated with Relugolix Combination Therapy: SPIRIT Extension Trial

Andrea S Lukes,1 Roberta Venturella,2 Krzysztof Dynowski,3 Rachel B Wagman,4 Julie S Perry,4 Yi Zhong,5 Viatcheslav G Rakov,6 Sylvia Mechsner,7 Neil P Johnson81Carolina Woman’s Research and Wellness Center, Durham, NC, USA; 2Department of C…

other 2026

Achieving Minimal-to-No Pain in Women with Endometriosis Treated with Relugolix Combination Therapy: SPIRIT Extension Trial

International journal of women's health ·doi:10.2147/IJWH.S603470

PURPOSE: Relugolix is an oral, non-peptide gonadotropin-releasing hormone receptor antagonist administered as once-daily combination therapy (relugolix-CT; 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) to reduce endometrios…

rct 2026

Achieving Minimal-to-No Pain in Women with Endometriosis Treated with Relugolix Combination Therapy: SPIRIT Extension Trial

·doi:10.2147/ijwh.s603470

Purpose: Relugolix is an oral, non-peptide gonadotropin-releasing hormone receptor antagonist administered as once-daily combination therapy (relugolix-CT; 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) to reduce endometrios…

observational 2026

Self-Reported Experiences of Women Taking Hormonal Treatments for Their Endometriosis and Uterine Fibroids Symptoms: Results from a Real-World Study in the US (MyEndoUF)

Elke Hunsche,1 Viatcheslav G Rakov,1 Jennifer Coppola,2 Sanjay K Agarwal31Formerly at Sumitomo Pharma Switzerland GmbH, Basel, Switzerland; 2Formerly at Sumitomo Pharma America Inc., Cambridge, MA, USA; 3Department of OBGYN & Reproductive S…

observational 2026

Self-Reported Experiences of Women Taking Hormonal Treatments for Their Endometriosis and Uterine Fibroids Symptoms: Results from a Real-World Study in the US (MyEndoUF)

International journal of women's health ·doi:10.2147/IJWH.S594255

PURPOSE: To characterize the experiences of individuals taking hormonal therapies to manage their symptoms of endometriosis (EM) or uterine fibroids (UF). PATIENTS AND METHODS: This prospective, 16-week observational study enrolled US part…

observational 2026

Self-Reported Experiences of Women Taking Hormonal Treatments for Their Endometriosis and Uterine Fibroids Symptoms: Results from a Real-World Study in the US (MyEndoUF)

·doi:10.2147/ijwh.s594255

Purpose: To characterize the experiences of individuals taking hormonal therapies to manage their symptoms of endometriosis (EM) or uterine fibroids (UF). Patients and Methods: This prospective, 16-week observational study enrolled US parti…

rct 2025

Efficacy and safety of relugolix combination therapy in women with uterine fibroids and adenomyosis: subgroup analysis of LIBERTY 1 and LIBERTY 2

Fertility and sterility ·doi:10.1016/j.fertnstert.2025.04.037

OBJECTIVE: To assess the effects of relugolix combination therapy in women with uterine fibroids (UFs) and concomitant ultrasound-diagnosed adenomyosis. DESIGN: This post hoc analysis used pooled data from completers of the pivotal LIBERTY…

observational 2025

Understanding Preferences, Needs, and Expectations for Pharmaceutical Treatment of Symptomatic Uterine Fibroids Based on Surveys of Healthcare Providers and Patients

International journal of women's health ·doi:10.2147/ijwh.s523846

BACKGROUND: Limited evidence is available regarding preferences of women with uterine fibroids (UF) and treating healthcare providers (HCPs) regarding treatment attributes; this evidence could contribute to patient-centered shared decision-…

qualitative 2023

Endometriosis Symptoms and Their Impacts on the Daily Lives of US Women: Results from an Interview Study

International journal of women's health ·doi:10.2147/ijwh.s409733

OBJECTIVE: This interview study sought to capture patients' experiences and perceptions of endometriosis symptoms and their impacts on daily life, as described by women in their own words. Using open-ended questions and a concept-elicitatio…